Table 2.
Regional differences in lipid-lowering therapy.
| Asia (N=2562) | Europe (N=2777) | Middle East (N=1031) | P value | |
|---|---|---|---|---|
| Statin monotherapy | 86.2% | 79.8% | 79.6% | <0.001 |
| Statin+ezetimibe | 7.7% | 11.6% | 14.6% | <0.001 |
| Statin+other non-statin | 5.3% | 6.7% | 5.0% | 0.047 |
| Non-statin monotherapy | 0.8% | 2.0% | 0.7% | <0.001 |
| Atorvastatin dose equivalent (mean±SD mg/day)a | 20±15 | 27±20 | 30±18 | <0.0001 |
| Atorvastatin dose equivalent (median [IQR] mg/day)a | 20 (10, 20) | 20 (10, 40) | 20 (20, 40) |
SD, standard deviation; IQR, interquartile range.
a
In statin treated patients.